Measuring cardiac power output -the acid test

See page 1496 for the article to which this Editorial refers
The heart is a pump, and as such consumes energy and produces work. These functions may be quantified by measuring myocardial oxygen consumption (MṼ O 2 ) and cardiac power output, respectively. Accurate measurement of these requires invasive techniques that may not always be appropriate or indeed ethical, but both can be estimated by noninvasive means. MṼ O 2 is closely mirrored by the double product of systolic blood pressure and heart rate [1] which are relatively simple to measure during a routine treadmill test. Cardiac power output also takes into account the stroke volume, so that the equation is similar to that used in electrical theory: W=V I That is:
Power output (Watts)=Pressure (Volts) Current (Amperes) or:
CPO=mean arterial pressure cardiac output (Qt) Both Qt and mean arterial pressure are more difficult to measure non-invasively than systolic blood pressure or heart rate. The study by Williams et al. [2] in this issue explains how [2] , and puts this elegant theoretical idea to the acid test -does the measurement of cardiac power output predict outcome in patients with heart failure more accurately than the current gold standard [3] , peak achieved whole body oxygen uptake (PṼ O 2 ).
PṼ O 2 itself is dependent on factors other than cardiac output, such as peripheral O 2 extraction, but PṼ O 2 and Qt mirror each other closely [4] . Both lung function [5] [6] [7] and peripheral skeletal function [8] are known to be altered in patients with heart failure, and hence may influence O 2 extraction. Furthermore, the consideration of (invasive) haemodynamic data in addition to the measurement of PṼ O 2 enhances its discriminatory power [9, 10] . The cardiac power output should reflect defects in cardiac performance alone, and hence be more specific than whole body PṼ O 2 . The results of this study [2] would appear to bear this out, in that power output was the only independent predictor of mortality in this group of patients. The next question then is whether it is worth the considerable extra effort and expertise necessary to perform the required tests?
The calculation of cardiac power output depends on the accurate measurement of Qt and mean arterial pressure both at rest and during exercise. Both can be problematic. Many methods have been described for the non-invasive measurement of Qt in man, an indication in itself that no method is entirely satisfactory. Examples include Doppler ultrasound of aortic blood flow [11] , radionuclide angiography [12] and bioimpedance cardiography [13] . In varying ways none of these tests is suitable for use during heavy exercise loads, and as they take time to perform, cannot by definition measure Qt max . In addition, the difficulties of cross-calibration with a reference (invasive) method such as dye-or thermodilution means that relative changes can de detected, but not absolute values, such as would be required in the calculation of cardiac power output. In contrast, the measurement of Qt by CO 2 rebreathing can be carried out during the course of a routine cardiopulmonary exercise test, provided the necessary hardware and software are available.
The method is accurate and reproducible at low and moderate levels of exercise [14] but again cannot measure Qt max as it takes up to 30 s to perform. The method is based on the Fick principle, but using CO 2 as the indicator substance:
Qt=Ṽ CO 2 / (CvCO 2 CaCO 2 ) where Ṽ CO 2 =Ṽ E (F E CO 2 ) Ṽ I (F I CO 2 ).
Minute expired volume (Ṽ E ) is measured directly, and inspired volume (Ṽ I ) derived from the Haldane correction [15] . F E CO 2 is measured in exhaled air breath-by-breath, and F I CO 2 assumed to be negligible. Because of the fast diffusion characteristics of CO 2 , the levels measured at the end of each breath (P ET CO 2 ) reflect the arterial pressure (PaCO 2 ), although this relationship may not be constant at high levels of exercise. The arterial content of CO 2 (CaCO 2 ) may then be calculated from PaCO 2 . If the subject then rebreathes into a closed circuit, the CO 2 concentration in the circuit rises until it equilibrates with the level in the pulmonary artery (mixed venous CO 2 , CvCO 2 ) [16] . Alternatively, the subject rebreathes from a bag pre-filled with a higher concentration of CO 2 until equilibrium is reached [14, 17] . From all these results Qt can be computed on-line and used in clinical studies to assess cardiac performance during exercise [4, 18] . The other component of the power output equation is mean arterial pressure (MAP). To calculate mean arterial pressure, systolic (SBP) and diastolic blood pressure (DBP) are measured during the exercise protocol, and the following equation applied:
MAP=DBP+1/3 (SBP DBP)
To measure mean arterial pressure non-invasively requires an aneroid or mercury sphygmomanometer, an arm cuff, and auscultation through a stethoscope, which can be increasingly difficult as the exercise test progresses. In particular, measurement of diastolic blood pressure during exercise may be inaccurate [19, 20] . It is possible therefore that an alternative and simpler measurement, using systolic blood pressure alone, might be more practical. Another option is to assess 'circulatory power' [21] , the product of systolic blood pressure and PṼ O 2 , both of which should be readily available from the results of the cardiopulmonary exercise test. Whichever option is chosen, it will be important in future studies to define the normal range for cardiac power output, which is not as yet clear, and to relate the values to other conventional indices of heart failure severity such as NYHA grade and neuroendocrine status.
Several interesting questions arise from consideration of cardiac power output. First, is the cardiac power output [2] a better prognostic indicator than the simpler 'circulatory power' [21] ? Second, would the cardiac power output be reduced in patients with left ventricular diastolic dysfunction, a group that has always been difficult to define by conventional means [22] but who have an abnormal neuroendocrine profile? [23] A new definition of heart failure could then include CPO max and also an unrelated index of cardiac dysfunction, such as increased circulating plasma levels of N-BNP [24] . The equipment needed to measure all the above would cost well under 100 000 Euros. The skill and experience to perform cardiopulmonary exercise testing reliably is more difficult to acquire, but necessary before such tests as described above can be attempted. Nevertheless, and in answer to the question we posed above, the extra effort is worthwhile as it further refines the prognostic power of PVO 2 in patients with heart failure. In this era of resource limitation, it is important to identify those at highest risk. Furthermore, the measurement of cardiac power output opens a new opportunity to improve our understanding of exercise physiology in such patients. Exercise testing is alive and well in the new Millenium.
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Curiously, dl-sotalol is largely used in the maintenance of sinus rhythm after conversion of atrial fibrillation, although its greater efficacy compared to pure beta-blockers has never been established. The article by Plewan et al. [1] in this issue is a good opportunity to formulate some reflexions about its efficacy compared to beta-blockers, and to make some remarks about the ways we prescribe antiarrhythmic agents and evaluate their effects.
Many studies have been published about the antiarrhythmic efficacy of sotalol. Most often, however, sotalol was compared to placebo, and the better efficacy of the active drug was attributed to its type III effect rather than to its ability to block betaadrenergic receptors. Until recently, no comparison was attempted with the reference type III drug that should be amiodarone. When such a comparison was done in permanent [2] as well as in recurrent [3] forms of atrial fibrillation the evident superiority of the reference drug was verified. This information was no big surprise for experienced clinicians.
